Name: Massimiliano Colella
New title: CEO, CMR Surgical
Previous title: Interim CEO, CMR Surgical
CMR Surgical, one of the robotics companies attempting to muscle into the soft tissue surgery market led by Intuitive Surgical, named Massimiliano Colella as its new CEO. Colella was appointed interim chief executive three months ago, and now has been promoted to the job permanently.
Colella was tapped to lead the Cambridge, England-based company after former CEO Supratim Bose resigned for personal reasons. The new CEO will also hold a seat on the board, according to the Tuesday announcement.
CMR hired Colella as chief commercial officer in 2023, tasked with helping to expand installations of the company’s Versius robot.
He previously worked for Evercare Group, a chain of hospitals, clinics and diagnostic centers, where he was group CEO and a board member. Colella has also held senior executive roles at Johnson & Johnson and Smith & Nephew and has more than 30 years of healthcare leadership experience.
CMR received the Food and Drug Administration’s de novo authorization for Versius in October, with an initial indication for gallbladder removal surgery. The company planned to partner with select hospitals in the first phase of the robot’s U.S. launch.
Versius secured Europe’s CE mark in 2019 and is the second-most-utilized robotic surgical system outside of the U.S., according to the company.
“With FDA marketing authorisation for Versius, and significant new products and instruments further strengthening the Versius offering, this is a very exciting time for CMR,” Colella said in a statement.
Versius’ compact and modular design, affordability and smaller-sized surgical instruments are some of its strengths, CMR Chief Medical Officer and co-founder Mark Slack told MedTech Dive in a recent interview. CMR plans to pursue additional indications for the robot in the U.S.
